What was the impact?
In 2005 Oxford Nanopore Technologies Ltd was formed, aiming to develop disruptive technologies based on Bayley’s and collaborators’ research, and
Bayley’s laboratory received a grant of $10 million from the US National Human Genome Research Institute. By 2012 Oxford Nanopore was valued at $2 billion, increasing to $3 billion in 2015.
To date the GridION, PromethION and MinION devices have been developed.
GridION is a nanopore-based system able to efficiently sequence DNA and RNA strands in terms of both cost and time; using 20 GridION nodes together an entire human genome could be sequenced in 15 minutes, at relatively low cost.
The GridION has since been superseded by the PromethION device, which can process multiple samples and enables greater workflow capability and scalability.
MinION is a miniaturised DNA sequencer, and is a portable device smaller than a mobile phone that plugs into a computer. MinION measures single molecules directly, without a need for the numerous processing stages prior to analysis required by traditional sequencing technology.
Oxford Nanopore Technologies’ MinION is the only near-market technology set to break the $1,000 target set by the US National Human Genome Research Institute.